Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment.

dc.contributor.author

Robertson, Allison G

dc.contributor.author

Swartz, Marvin S

dc.coverage.spatial

United States

dc.date.accessioned

2017-04-03T18:36:12Z

dc.date.available

2017-04-03T18:36:12Z

dc.date.issued

2017-02-28

dc.description.abstract

With insufficient access to treatment and a tradition of criminalizing addiction, people with substance use disorders - including opioid dependence - are more likely to be incarcerated than they are to receive the treatment they need. Drug treatment courts aim to address this problem, engaging their participants in substance use treatment in lieu of incarceration. Drug courts offer an especially important window of opportunity to connect opioid-dependent participants to extended-release naltrexone (XR-NTX), at a time when they are under highly-structured court supervision and required to detoxify from opioids to participate. Given the high cost of XR-NTX and high rates of uninsurance in the drug court population, new rigorous cost-effectiveness evidence is needed to demonstrate the extent to which XR-NTX improves program outcomes, including by reducing recidivism. With that new evidence, drug courts and the counties in which they are situated can make informed and difficult policy decisions about funding XR-NTX for some of their highest-risk community members.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/28274648

dc.identifier

S0740-5472(16)30475-5

dc.identifier.eissn

1873-6483

dc.identifier.uri

https://hdl.handle.net/10161/13938

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

J Subst Abuse Treat

dc.relation.isversionof

10.1016/j.jsat.2017.02.016

dc.subject

Cost-effectiveness

dc.subject

Drug treatment courts

dc.subject

Extended-release naltrexone

dc.subject

Recidivism

dc.title

Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment.

dc.type

Journal article

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/28274648

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Psychiatry & Behavioral Sciences, Social and Community Psychiatry

pubs.organisational-group

Sanford School of Public Policy

pubs.organisational-group

Sanford School of Public Policy - Secondary Group

pubs.organisational-group

School of Medicine

pubs.publication-status

Published online

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Robertson Swartz. MAT drug court commentary. JSAT 2017.pdf
Size:
219.69 KB
Format:
Adobe Portable Document Format
Description:
Published version